HeartStent Corp.
This article was originally published in The Gray Sheet
Executive Summary
Early stage cardiovascular device firm completes a $12.8 mil. private financing round. Under development is the HeartStent direct revascularization device intended for coronary artery disease patients currently treated with coronary artery bypass grafts. The less invasive system is placed "through the ventricular wall" to supply blood to a coronary artery directly from the left ventricle of the heart, the St. Paul, Minnesota firm explains. Pre-clinical studies "prove feasibility" of the approach, which eliminates the need for artery or vein harvesting, cuts procedure time, and can be performed on a beating heart, HeartStent claims. Lead investors include Kleiner Perkins, Technology Partners, U.S. Bancorp Piper Jaffray Ventures, St. Paul Ventures, and Charter Growth Capital